Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients

Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications d...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Valerio Voglino, Giorgio Persano, Alessandro Crocoli, Aurora Castellano, Annalisa Serra, Ugo Giordano, Gian Luigi Natali, Pier Luigi Di Paolo, Cristina Martucci, Alessandra Stracuzzi, Alessandro Inserra
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/88b22044d91e47e88c3228e5caa30ffb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:88b22044d91e47e88c3228e5caa30ffb
record_format dspace
spelling oai:doaj.org-article:88b22044d91e47e88c3228e5caa30ffb2021-11-16T06:57:01ZHemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients2296-236010.3389/fped.2021.761896https://doaj.org/article/88b22044d91e47e88c3228e5caa30ffb2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fped.2021.761896/fullhttps://doaj.org/toc/2296-2360Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications during induction chemotherapy.Aim: To find easily and rapidly assessed parameters that help clinicians identify those patients affected by high-risk neuroblastoma who have an additional risk of hemorrhagic complications.Methods: The clinical notes of patients diagnosed with high-risk neuroblastoma from January 2013 until February 2021 were retrospectively reviewed. Clinical, demographic and laboratory data, biological characteristics of the tumor, and information about treatment and hospital stay were identified.Results: In the examined period, 44 patients were diagnosed with high-risk neuroblastoma. Four of these patients had hemorrhagic complications within 2–7 days after the initiation of induction chemotherapy; two patients had hemothorax, one patient had hemoperitoneum and one patient had hemothorax and hemoperitoneum. The patient with isolated hemoperitoneum was treated with blood components transfusions, clotting factors and colloids infusions; the three patients with hemothorax underwent thoracostomy tube placement and respiratory support. At initial presentation, patients who suffered from hemorrhagic complications had a higher degree of hypertension (stage 2, p = 0.0003), higher levels of LDH (median 3,745 U/L, p = 0.009) and lower levels of hemoglobin (mean 7.6 gr/dl, p = 0.0007) compared to other high-risk patients.Conclusions: A subgroup of “additional” high-risk patients can be identified within the high-risk neuroblastoma patients based on mean arterial pressure, LDH levels and hemoglobin levels at presentation. Further studies to define cut-off values and optimal management strategies for these patients are needed.Valerio VoglinoGiorgio PersanoAlessandro CrocoliAurora CastellanoAnnalisa SerraUgo GiordanoGian Luigi NataliPier Luigi Di PaoloCristina MartucciAlessandra StracuzziAlessandro InserraFrontiers Media S.A.articlehigh-risk neuroblastomahemorrhagic complicationshemothoraxhemoperitoneumchemotherapy complicationsPediatricsRJ1-570ENFrontiers in Pediatrics, Vol 9 (2021)
institution DOAJ
collection DOAJ
language EN
topic high-risk neuroblastoma
hemorrhagic complications
hemothorax
hemoperitoneum
chemotherapy complications
Pediatrics
RJ1-570
spellingShingle high-risk neuroblastoma
hemorrhagic complications
hemothorax
hemoperitoneum
chemotherapy complications
Pediatrics
RJ1-570
Valerio Voglino
Giorgio Persano
Alessandro Crocoli
Aurora Castellano
Annalisa Serra
Ugo Giordano
Gian Luigi Natali
Pier Luigi Di Paolo
Cristina Martucci
Alessandra Stracuzzi
Alessandro Inserra
Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
description Background: Neuroblastoma is the most common solid extracranial tumor in children. Patients affected by neuroblastoma are stratified into low, intermediate, and high risk in terms of event-free and overall survival. Some high-risk patients have an additional risk of acute hemorrhagic complications during induction chemotherapy.Aim: To find easily and rapidly assessed parameters that help clinicians identify those patients affected by high-risk neuroblastoma who have an additional risk of hemorrhagic complications.Methods: The clinical notes of patients diagnosed with high-risk neuroblastoma from January 2013 until February 2021 were retrospectively reviewed. Clinical, demographic and laboratory data, biological characteristics of the tumor, and information about treatment and hospital stay were identified.Results: In the examined period, 44 patients were diagnosed with high-risk neuroblastoma. Four of these patients had hemorrhagic complications within 2–7 days after the initiation of induction chemotherapy; two patients had hemothorax, one patient had hemoperitoneum and one patient had hemothorax and hemoperitoneum. The patient with isolated hemoperitoneum was treated with blood components transfusions, clotting factors and colloids infusions; the three patients with hemothorax underwent thoracostomy tube placement and respiratory support. At initial presentation, patients who suffered from hemorrhagic complications had a higher degree of hypertension (stage 2, p = 0.0003), higher levels of LDH (median 3,745 U/L, p = 0.009) and lower levels of hemoglobin (mean 7.6 gr/dl, p = 0.0007) compared to other high-risk patients.Conclusions: A subgroup of “additional” high-risk patients can be identified within the high-risk neuroblastoma patients based on mean arterial pressure, LDH levels and hemoglobin levels at presentation. Further studies to define cut-off values and optimal management strategies for these patients are needed.
format article
author Valerio Voglino
Giorgio Persano
Alessandro Crocoli
Aurora Castellano
Annalisa Serra
Ugo Giordano
Gian Luigi Natali
Pier Luigi Di Paolo
Cristina Martucci
Alessandra Stracuzzi
Alessandro Inserra
author_facet Valerio Voglino
Giorgio Persano
Alessandro Crocoli
Aurora Castellano
Annalisa Serra
Ugo Giordano
Gian Luigi Natali
Pier Luigi Di Paolo
Cristina Martucci
Alessandra Stracuzzi
Alessandro Inserra
author_sort Valerio Voglino
title Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_short Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_full Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_fullStr Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_full_unstemmed Hemorrhage During Induction Chemotherapy in Neuroblastoma: Additional Risk Factors in High-Risk Patients
title_sort hemorrhage during induction chemotherapy in neuroblastoma: additional risk factors in high-risk patients
publisher Frontiers Media S.A.
publishDate 2021
url https://doaj.org/article/88b22044d91e47e88c3228e5caa30ffb
work_keys_str_mv AT valeriovoglino hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT giorgiopersano hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT alessandrocrocoli hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT auroracastellano hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT annalisaserra hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT ugogiordano hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT gianluiginatali hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT pierluigidipaolo hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT cristinamartucci hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT alessandrastracuzzi hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
AT alessandroinserra hemorrhageduringinductionchemotherapyinneuroblastomaadditionalriskfactorsinhighriskpatients
_version_ 1718426677968633856